High-density lipoprotein cholesterol and the role of statins

Circulation Journal

Volumn 66, Issue 11, 2002, Pages 1037-1044

  Chong, Pang H ^a,b   Kezele, Robert ^a   Franklin, Cory ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Jr Hospital of Cook County   (United States)

Author keywords

Cardiovascular risk factor; High density lipoprotein cholesterol; Reverse cholesterol transport; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; META ANALYSIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0036859822     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.66.1037     Document Type: Article

References (84)

1. Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 2001; 57(Suppl 2): S35-S44.
2. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABCI controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104: R25-R31.
3. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, et al. High-density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ABCI. Proc Natl Acad Sci USA 2000; 97: 4245-4250.
4. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: An observational study. Lancet 2002; 359: 37-42.
5. Gordon DJ, Rifkind BM. High-density lipoproteins-the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316.
6. Goldbourt U, Yaaris S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997; 17: 107-113.
7. Hegele RA, Harris SB, Brunt JH, Young TK, Hanley AJ, Zinman B, et al. Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Arteriosclerosis 1999; 146: 153-160.
8. Tyroler HA, Glueck CJ, Christensen B, Kwiterovich PO Jr. Plasma high-density lipoprotein cholesterol comparisons in black and white populations: The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV99-IV107.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977; 62: 707-714.
10. Assmann G, Schulte H. Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study. Drugs 1990; 40(Suppl 1): 13-18.
11. Johansson S, Wiklund O, Karlsson T, Hjalmarson A, Emanuelsson H. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Eur Heart J 1991; 12: 1020-1028.
12. Roth A, Eshchar Y, Keren G, Sheps D, Kerbals S, Laniado S. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1994; 73: 1154-1158.
13. Dzavik V, Teo K, Yokoyama S, Modi R, Dinwoodie A, Burton JR, et al. Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240mg/dl and triglycerides <350 mg/dl. Am J Cardiol 1995; 75: 936-938.
14. Miller M, Seidler A, Kwiterovich P, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 1992; 86: 1165-1170.
15. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
16. Miller N. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589-597.
17. Kashyap ML. Mechanism studies of high-density lipoproteins. Am J Cardiol 1998; 82: 42U-48U.
18. Gordon DJ. Factors affecting high-density lipoproteins. Endocrinol Metab Clin North Am 1998; 27: 699-709.
19. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999; 159: 1049-1057.
20. Tonkin A. High-density lipoprotein cholesterol and treatment guidelines. Am J Cardiol 2001; 88(Suppl): 41N-44N.
21. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
22. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
24. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
25. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
26. Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadak KN, Zannis V. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000; 11: 106-115.
27. Miller N. Pharmacological intervention for altering lipid metabolism. Drugs 1990; 40(Suppl 1): 26-32.
28. Farnier M. Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol 1998; 82: 3J-10J.
29. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol 2000; 86(Suppl): 5L-10L.
30. Von Eckardstein A, Nofer J, Assmann G. High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-17.
31. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144: 177-184.
32. Martin G, Duez H, Blanquart C, Bersezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apo A-I. J Clin Invest 2000; 107: 1423-1432.
33. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Kuijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.
34. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, et al. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993; 92: 1650-1658.
35. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Arterioscler Thromb Vasc Biol 1997; 17: 1053-1059.
36. Tall A, Jiang X, Silver D. 1999 George Lyman Duff Memorial Lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 1185-1188.
37. Rader DJ. Protective effects of HDL-C and need to raise low levels explored. Am J Manag Care 2002; Jan(Suppl): 2,5.
38. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
39. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reductions of LDL cholesterol by 25% to 60% in patients with primary hypercholestemlemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-682.
40. Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-197.
41. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44.
42. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin Study Group. Am J Cardiol 1997; 79: 1475-1481.
43. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, doublemasked study. Clin Ther 1996; 18: 853-863.
44. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996; 36: 604-609.
45. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-587.
46. Peters TK, Muratti EN, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolemia. Drugs 1994; 47(Suppl 2): 64-72.
47. Langtry HD, Markham A. Fluvastatin: A review of its use in lipid disorders. Drugs 1999; 57: 583-606.
48. Ballantyne CM, Pazzucconi F, Pinto X, Reckless JP, Stein E, McKenney J, et al. Efficacy and tolerability of fluvastatin extendedrelease delivery system: A pooled analysis. Clin Ther 2001; 23: 177-192.
49. Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 2000; 86: 406-411.
50. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-49.
51. Steinhage-Thiessen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia: Simvastatin Pravastatin European Study Group. Cardiology 1994; 85: 244-254.
52. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810-815.
53. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
54. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholestererolemia: The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther 1992; 14: 708-717.
55. Douste-Blazy P, Ribeiro VG, Seed M and the European Study Group. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Drugs Invest 1993; 6: 353-361.
56. Lambrecht LJ, Malini PL. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia: European Study Group. Acta Cardiol 1993; 48: 541-544.
57. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol 1998; 82: 311-316.
58. Crouse JR 3rd, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoproteins cholesterol and apolipoprotein A-1. Am J Cardiol 1999; 83: 1476-1477.
59. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999; 53: 609-611.
60. Brown AS, Bakker-Arkema RG, Yellen L, Henley RW Jr, Guthrie R, Campbell CF, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665-672.
61. Ma P, Hegele R, Yale JF, Schwartz B. CAVEAT: A randomized, double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidemia. Br J Cardiol 2000; 7: 780-786.
62. Schaefer JR, Schweer H, Ikewaki K, Stracke H. Seyberth HJ, Kaffarnik H, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144: 177-184.
63. Kastelein JJ. Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86: 221-223.
64. Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, ChatenetDuchene L, et al. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis 1999; 143: 415-425.
65. Guerin M, Lassel TS, Le Goff W, Famier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20: 189-197.
66. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen-year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
67. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992; 85: 37-45.
68. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
69. Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA 1989; 262: 3148-3153.
70. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994; 154: 73-82.
71. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023.
72. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al for the Scandianvian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-1460.
73. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-3051.
74. Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J Am Coll Cardiol 1999; 33: 125-130.
75. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278 -286.
76. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, et al. Influence of low HDL on progression of coronary artery disease and response to fiuvastatin therapy. Circulation 1999; 99: 736-743.
77. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-484.
78. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-1822.
79. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: Evidence from large-scale statin and fibrate trials. Am J Cardiol 2001; 88(Suppl): 14N-18N.
80. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustainedrelease niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992: 69: 1083-1085.
81. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited: Findings from the Helsinki Heart Study. Arch Intern Med 1994; 154: 2714-2720.
82. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-651.
83. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
84. Kashyap ML, McGovern ME, Berra K, Guyton FR, Kwiterovich PO, Harper FWL, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia, Am J Cardiol 2002; 89: 672-678.